Haemate (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate is indicated for several clinical situations involving deficiencies of factor VIII and von Willebrand factor.

• Treatment of bleeding episodes in patients with hemophilia A.
• Management of all types of von Willebrand disease, including type 1, 2, and 3.
• Prophylactic therapy before surgical or invasive procedures in individuals with combined factor VIII and von Willebrand factor deficiency.
• Long‑term prophylaxis to reduce the frequency of spontaneous bleeds in severe hemophilia A.
• Replacement therapy in patients with combined factor VIII and von Willebrand factor deficiency when on‑demand treatment is required.

Adverse reactions to Haemate have been reported; they vary in frequency and severity.

Common

• Headache
• Fever or chills
• Nausea or vomiting
• Injection site reactions such as redness or swelling

Serious

• Development of inhibitors (antibodies) against factor VIII or von Willebrand factor
• Allergic reactions including rash, urticaria, or anaphylaxis
• Thromboembolic events such as deep‑vein thrombosis
• Renal or hepatic dysfunction in rare cases

Before initiating Haemate, clinicians should evaluate several safety considerations to minimize risk.

• Assess for a history of inhibitors to factor VIII or von Willebrand factor.
• Verify patient’s baseline liver and kidney function tests.
• Use caution in patients with a known hypersensitivity to plasma‑derived products.
• Monitor for signs of thrombosis, especially in individuals with cardiovascular risk factors.
• Consider pregnancy status; safety data are limited.
• Review concurrent anticoagulant or antiplatelet therapy.
• Ensure proper storage and handling to maintain product integrity.

Haemate may interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid

• Concomitant use of other plasma‑derived clotting factor concentrates without medical supervision.
• Simultaneous administration of high‑dose pro‑coagulant agents that could increase thrombosis risk.

Use with caution

• Antifibrinolytic agents such as tranexamic acid; monitor for excessive clot formation.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants); adjust dosing and monitor coagulation parameters.
• Immunosuppressive drugs that may affect inhibitor development.
• Vaccines administered intramuscularly; observe for local reactions.